인데놀정40mg 효능·효과
등록된 내용이 없습니다.
광고
인데놀정40mg 복용법 (용법·용량)
등록된 내용이 없습니다.
인데놀정40mg 부작용·주의사항
전체 10개 항목 펼치기/접기
1. 다음 환자에는 투여하지 말 것.
2. 다음 환자에는 신중히 투여할 것.
3. 이상반응
4. 일반적 주의
5. 상호작용
6. 임부 및 수유부에 대한 투여
7. 소아에 대한 투여
8. 고령자에 대한 투여
9. 과량 투여시의 처치
10. 임상검사치에 대한 영향
인데놀정40mg 성분·함량
1정 중 200밀리그램 기준
| 성분 | 영문 | 분량 |
|---|---|---|
| 프로프라놀롤염산염 | Propranolol Hydrochloride | 40 밀리그램 |
인데놀정40mg 낱알 모양 (식별 표시)
- 모양
- 원형 · 나정
- 색
- 하양
- 표시(앞/뒤)
- DK40 / 분할선
- 분할선
- - / -
- 크기
- 9 × 9 mm, 두께 2.7mm
📍 인데놀정40mg 살 수 있는 내 주변 약국
전문의약품은 의사 처방전이 있어야 약국에서 받을 수 있습니다. 재고는 약국에 전화로 확인하세요.
🗺️ 지도에서 찾기🌐 해외(미국) 정보 — 프로프라놀롤염산염
미국 FDA·NLM 자료 · 2026-10-04 기준이 성분은 한국어 번역이 없습니다(검수 전 자동 번역 게시는 멈춰 두었습니다). 아래는 미국 FDA 원문입니다 — 원문 라벨(DailyMed).
미국에서 쓰이는 곳(적응증)
영어 원문 (미국 FDA 라벨)
Hypertension Propranolol Hydrochloride Extended-Release Capsules, USP, are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol Hydrochloride Extended-Release Capsules, USP, are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol Hydrochloride Extended-Release Capsules, USP, are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Migraine Propranolol Hydrochloride Extended-Release Capsules, USP, are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Hypertrophic Subaortic Stenosis Propranolol Hydrochloride Extended-Release Capsules, USP, improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.
⚠️ 박스 경고(가장 강한 경고)
영어 원문 (미국 FDA 라벨)
Angina Pectoris There have been reports of exacerbation of angina and, in some cases, myocardial infarction, following abrupt discontinuance of propranolol therapy. Therefore, when discontinuance of propranolol is planned, the dosage should be gradually reduced over at least a few weeks, and the patient should be cautioned against interruption or cessation of therapy without the physician's advice. If propranolol therapy is interrupted and exacerbation of angina occurs, it usually is advisable to reinstitute propranolol therapy and take other measures appropriate for the management of unstable angina pectoris. Since coronary artery disease may be unrecognized, it may be prudent to follow the above advice in patients considered at risk of having occult atherosclerotic heart disease who are given propranolol for other indications.
쓰면 안 되는 경우
영어 원문 (미국 FDA 라벨)
Propranolol is contraindicated in 1) cardiogenic shock; 2) sinus bradycardia and greater than first-degree block; 3) bronchial asthma; and 4) in patients with known hypersensitivity to propranolol hydrochloride.
주요 경고·주의
영어 원문 (미국 FDA 라벨)
Angina Pectoris There have been reports of exacerbation of angina and, in some cases, myocardial infarction, following abrupt discontinuance of propranolol therapy. Therefore, when discontinuance of propranolol is planned, the dosage should be gradually reduced over at least a few weeks, and the patient should be cautioned against interruption or cessation of therapy without the physician's advice. If propranolol therapy is interrupted and exacerbation of angina occurs, it usually is advisable to reinstitute propranolol therapy and take other measures appropriate for the management of unstable angina pectoris. Since coronary artery disease may be unrecognized, it may be prudent to follow the above advice in patients considered at risk of having occult atherosclerotic heart disease who are given propranolol for other indications. Hypersensitivity and Skin Reactions Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, have been associated with the administration of propranolol (see ADVERSE REACTIONS ). Cutaneous reactions, including Stevens-Johnson Syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, and urticaria, have been reported with use of propranolol (see ADVERSE REACTIONS ). Cardiac Failure Sympathetic stimulation may be a vital component supporting circulatory function in patients with congestive heart failure, and its inhibition by beta blockade may precipitate more severe failure. Although beta-blockers should be …
임신·특수 환자
영어 원문 (미국 FDA 라벨)
Pregnancy Pregnancy Category C In a series of reproductive and developmental toxicology studies, propranolol was given to rats by gavage or in the diet throughout pregnancy and lactation. At doses of 150 mg/kg/day, but not at doses of 80 mg/kg/day (equivalent to the MRHD on a body surface area basis), treatment was associated with embryotoxicity (reduced litter size and increased resorption rates) as well as neonatal toxicity (deaths). Propranolol hydrochloride also was administered (in the feed) to rabbits (throughout pregnancy and lactation) at doses as high as 150 mg/kg/day (about 5 times the maximum recommended human oral daily dose). No evidence of embryo or neonatal toxicity was …
미국 부작용 보고(FAERS)에 많이 나온 증상
미국 FDA에 접수된 이 성분 관련 보고 71,662건 가운데 많이 적힌 증상입니다. 보고 수는 약 때문이라는 증거가 아니며, 많이 쓰는 약일수록 많아집니다. 증상 이름의 한국어는 AI 번역(참고용)이라 영어 원어를 함께 적었습니다.
- 1 적응증 외 사용off label use7,918
- 2 약효 없음drug ineffective5,617
- 3 오심nausea4,552
- 4 두통headache3,962
- 5 피로fatigue3,912
- 6 설사diarrhoea3,295
- 7 어지러움dizziness3,222
- 8 미승인 적응증 사용product use in unapproved indication3,114
- 9 구토vomiting2,778
- 10 호흡 곤란dyspnoea2,675
- 11 제품 사용 문제product use issue2,595
- 12 통증pain2,424
미국 리콜 기록
FDA 리콜(회수) 기록 2건 중 최근 2건 — 특정 회사·제조번호 제품의 회수로, 국내 제품과는 관계없을 수 있습니다.
- 2024.01.03 · 2등급 · CARDINAL HEALTHCARE CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
- 2014.08.27 · 2등급 · Fresenius Kabi USA, LLC CGMP Deviations: Citations given to API supplier by the Italian Health Agency AIFA for several critical deficiencies which caused a recall of the API lot used to manufacture Propanolo HCl Injection.
출처: 미국 FDA openFDA(라벨·FAERS·리콜), 미국 국립의학도서관 RxNorm · DailyMed 원문 라벨. 한국어는 오픈드럭 서버 AI(gemma)가 자동 번역한 참고용(사람 검수 전)으로 오역이 있을 수 있으니 반드시 원문을 확인하세요.
허가 정보
- 품목기준코드
- 197600046
- 허가 구분
- 신고 · 완제의약품
- 상태
- 정상
- 저장 방법
- 차광 밀폐용기
- 사용 기간
- 제조일로부터 24 개월
- 포장 단위
- 1000정/병
- ATC 코드
- C07AA05
- 보험 코드
- 645902480
- 표준코드
- 8806459024800, 8806459024817, 8806459024824
- 최근 변경
- 2025.10.31
허가 변경 이력
- · 용법·용량, 2025-10-31
- · 저장방법 및 사용(유효)기간, 2025-10-31
- · 사용상주의사항변경(부작용포함), 2020-09-03
- · 효능효과변경, 2015-12-17
- · 용법용량변경, 2015-12-17
- · 사용상주의사항변경(부작용포함), 2015-12-17
- · 제품명칭변경, 2011-05-18
- · 사용상주의사항변경(부작용포함), 2009-11-07
- · 사용상주의사항변경(부작용포함), 2003-06-27
원문: 식약처 의약품안전나라